<DOC>
	<DOCNO>NCT02724098</DOCNO>
	<brief_summary>The aim study investigate pharmacokinetics subcutaneously administer dexmedetomidine healthy volunteer . The absolute bioavailability subcutaneously administer dexmedetomidine calculate . In addition , investigator report effect subcutaneously administer dexmedetomidine plasma catecholamine level , vital sign systemic blood pressure , heart rate sedation . The investigator also monitor local systemic safety tolerability subcutaneously administer dexmedetomidine .</brief_summary>
	<brief_title>Bioavailability Subcutaneous Dexmedetomidine</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Fluent skill Finnish language order able give inform consent communicate study personnel . Age ≥ 18 year . Male gender . Weight ≥ 60 kg . Written inform consent subject . Previous history intolerance study drug relate compound additive . Concomitant drug therapy kind except paracetamol 14 day prior study . Existing recent significant disease . History kind drug allergy . Previous present alcoholism , drug abuse , psychological emotional problem likely invalidate inform consent , limit ability subject comply protocol requirement . Donation blood within six week prior study . Body weight &lt; 60 kg BMI &gt; 30 kg / m2 . Participation clinical study involve investigational market drug product concomitantly within one month prior entry study . Smoking one month start study study period . Clinically significant abnormal finding physical examination , ECG laboratory screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Palliative Therapy</keyword>
</DOC>